Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.46 |
| ▸ | ITK | Q08881 | 4/20 | 0.46 |
| ▸ | MAPK3 | P27361 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | KDR | P35968 | 5/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12265220 | 0.91 | EGFR (0.45) | EGFRITKMAPK3CA12CA1 | |
| SCHEMBL17371332 | 0.80 | EGFR (0.46) | EGFRITKMAPK3CA12CA1 | |
| SCHEMBL16123201 | 0.80 | EGFR (0.49) | EGFRITKKDR | |
| SCHEMBL8457415 | 0.79 | TSHR (0.54) | CA12CA1CA2CA9 | |
| SCHEMBL7345964 | 0.78 | LMNA (0.49) | — | |
| SCHEMBL7778277 | 0.78 | BRD4 (0.52) | BRD4 | |
| SCHEMBL17958060 | 0.77 | CA12 (0.50) | CA12CA1CA2CA9BRD4 | |
| SCHEMBL1236314 | 0.77 | CA12 (0.48) | CA12CA1CA2CA9BRD4 | |
| SCHEMBL15573936 | 0.76 | TSHR (0.56) | CA12CA1CA2CA9 | |
| SCHEMBL18165160 | 0.74 | CA12 (0.47) | CA12CA1CA2CA9BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2475375-A2 | PI3 KINASE INHIBITORS AND USES THEREOF | Avila Therapeutics, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| WO-2011031896-A2 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011031896-A2 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | PIK3CA, PIK3CB, PIK3C2B | EGFR 580/4885ITK 557/4885MAPK3 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.